|

Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer

RECRUITINGSponsored by Santa Chiara Hospital
Actively Recruiting
SponsorSanta Chiara Hospital
Started2023-01-01
Est. completion2026-12-31
Eligibility
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06783127

Summary

This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.

Eligibility

Sex: MALEHealthy volunteers accepted
Inclusion Criteria:

BRCA mutant Metastatic castration-resistant prostate cancer patients treatment with olaparib in clinical practice

Exclusion Criteria:

Olaparib treatment in a clinical trial

Conditions4

BRCA MutationCancerCastrate Resistant Prostate CancerProstate Cancer

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.